Involvement of NMDA receptors in the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice

Behavioural Brain Research

Volumn 231, Issue 1, 2012, Pages 138-145

  Almasi Nasrabadi, Mina ^a,b   Javadi Paydar, Mehrak ^a,b   Mahdavian, Shirin ^a,b   Babaei, Rosa ^a,b   Sharifian, Maedeh ^a,b   Norouzi, Abbas ^b   Dehpour, Ahmad Reza ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Glutamatergic pathway; Memory; Mice; MK 801; NMDA; Pioglitazone

Indexed keywords

DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PIOGLITAZONE; SCOPOLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; MALE; MAZE TEST; MEMORY DISORDER; MENTAL PERFORMANCE; MOUSE; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; SPATIAL MEMORY;

ANIMALS; AVOIDANCE LEARNING; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; HYPOGLYCEMIC AGENTS; MAZE LEARNING; MEMORY; MEMORY DISORDERS; MICE; MUSCARINIC ANTAGONISTS; RECEPTORS, N-METHYL-D-ASPARTATE; SCOPOLAMINE HYDROBROMIDE; THIAZOLIDINEDIONES;

EID: 84859331557     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.03.006     Document Type: Article

References (59)

1. Berger J., Moller D.E. The mechanisms of action of PPARs. Annu Rev Med 2002, 53:409-435.
2. David S.G., Mark H.L.L., JoAnne M. Ciglitazone increases basal cytokine expression in the central nervous system of adult rats. Brain Res 2005, 1034:139-146.
3. Roses A.D., Saunders A.M., Huang Y., Strum J., Weisgraber K.H., Mahley R.W. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenic hypothesis (Alzheimer's disease). J Pharmacogenomics 2007, 7:10-28.
4. Bordet R., Ouk T., Petrault O., Gele P., Gautier S., Laprais M., et al. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 2006, 34:1341-1346.
5. Ricote M., Huang J.T., Welch J.S., Glass C.K. The peroxisome proliferators receptor gamma as a regulator of monocyte/macrophage function. J Leukoc Biol 1999, 66:733-739.
6. Jing C., Ting A.T., Seed B. PPAR gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86.
7. Stevenson R.W., McPherson R.K., Genereux P.E., Danbury B.H., Kreutter D.K. Antidiabetic agent englitazone enhances insulin action in nondiabetic rats without producing hypoglycemia. Metabolism 1991, 40:1268-1274.
8. Fujiwara T., Okuno A., Yoshioka S., Horikoshi H. Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism 1995, 44:486-490.
9. Stumvoll M., Haring H.U. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002, 34:217-224.
10. Hanyu H., Sato T., Kiuchi A., Sakurai H., Iwamoto T. Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr 2009, 57:177-179.
11. Watson G.S., Cholerton B.A., Reger M.A., Baker L.D., Plymate S.R., Asthana S., et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005, 13:950-958.
12. Xing B., Xin T., Hunter R.L., Bing G. Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt. J Neuroinflammation 2008, 5:4.
13. Hunter R.L., Choi D.Y., Ross S.A., Bing G. Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats. Neurosci Lett 2008, 432:198-201.
14. Kumar P., Kaundal R.K., More S., Sharma S.S. Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease. Behav Brain Res 2009, 197:398-403.
15. Jiang Q., Heneka M., Landreth G.E. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs 2008, 22:1-14.
16. Romera C., Hurtado O., Mallolas J., Pereira M.P., Morales J.R., Romera A., et al. Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection. J Cereb Blood Flow Metab 2007, 27:1327-1338.
17. 2+ currents by PPAR-gamma agonists in cultured hippocampal neurons. J Neurochem 2009, 109:1800-1811.
18. Tombaugh G.C., Rowe W.B., Rose G.M. The slow after hyperpolarization in hippocampalCA1 neurons covaries with spatial learning ability in aged Fisher 344 rats. J Neurosci 2005, 25:2609-2616.
19. Murphy G.G., Shah V., Hell J.W., Silva A.J. Investigation of age-related cognitive decline using mice as a model system: neurophysiological correlates. Am J Geriatr Psychiatry 2006, 14:1012-1021.
20. 2+ disruption in Alzheimer's disease by presenilin regulation of InsP(3) receptor channel gating. Neuron 2008, 58:871-883.
21. Riedel G., Platt B., Micheau J. Glutamate receptor function in learning and memory. Behav Brain Res 2003, 140:1-47.
22. Myhrer T. Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks. Brain Res Brain Res Rev 2003, 41:268-287.
23. Ghafari M., Patil S.S., Hoger H., Pollak A., Lubec G. NMDA-complexes linked to spatial memory performance in the Barnes maze in CD1 mice. Behav Brain Res 2011, 221:142-148.
24. Gardoni F., Kamal A., Bellone C., Biessels G.J., Ramakers G.M., Cattabeni F., et al. Effects of streptozotocin-diabetes on the hippocampal NMDA receptor complex in rats. J Neurochem 2002, 80:438-447.
25. Dellu F., Mayo W., Cherkaoui J., Moal L.M., Simon H. A two-trial memory task with automated recording: study in young and aged rats. Brain Res 1992, 588:132-139.
26. Allami N., Javadi-Paydar M., Rayatnia F., Sehhat K., Rahimian R., Norouzi A., et al. Suppression of nitric oxide synthesis by l-NAME reverses the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice. Eur J Pharmacol 2011, 650:240-248.
27. Elangbam C.S., Tyler R.D., Lightfoot R.M. Peroxisome proliferator activated receptors in atherosclerosis and inflammation: an update. Toxicol Pathol 2001, 29:224-231.
28. Chawla A., Schwartz E.J., Dimaculangan D.D., Lazar M.A. Peroxisome proliferator-activated receptor (PPAR) g: adipose-predominant expression and induction early in adipose differentiation. Endocrinology 1994, 135:798-800.
29. Desvergne B., Michalik L., Wahli W. Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol Endocrinol 2004, 18:1321-1332.
30. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002, 18:10-15.
31. Braissant O., Foufelle F., Scotto C., Dauca M., Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996, 137:354-366.
32. Moreno S., Farioli-Vecchioli S., Ceru M.P. Immunolocalization of peroxisome proliferator-activated receptors and retionoid X receptors in the adult rat CNS. Neuroscience 2004, 123:131-145.
33. Deplanque D., Gele P., Petrault O., Six I., Furman C., Bonly M., et al. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 2003, 23:6264-6271.
34. Ogata T., Miyauchi T., Sakai S., Irukayama-Tomobe Y., Goto K., Yamaguchi I. Stimulation of peroxisome proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. Clin Sci (Lond) 2002, 103:284-288.
35. Sundarajan S., Gamboa J.L., Victor N.A., Wanderi E.W., Lust W.D., Landreth G.E. Peroxisome proliferator-activated receptor-ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 2005, 130:685-696.
36. Park S.W., Yi J.H., Miranpuri G., Satriotomo I., Bowen K., Resnick D.K., et al. Thiazolidinedione class of peroxisome proliferator-activated receptor-gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain and inflammation after spinal cord injury in adult rats. J Pharm Exp Therap 2007, 320:1002-1012.
37. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002, 82:615-624.
38. Diab A., Deng C., Smith J.D., Hussain R.Z., Phanavanh B., Lovett-Racke A.E., et al. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-((12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002, 168:2508-2515.
39. Feinstein D.L., Spagnolo A., Akar C., Weinberg G., Murphy P., Gavrilyuk V., et al. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key. Biochem Pharmacol 2005, 70:177-188.
40. Collino M., Aragno M., Mastrocola R., Gallicchio M., Rosa A.C., Dianzani C., et al. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol 2006, 530:70-80.
41. Francis P.T., Palmer A.M., Snape M., Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999, 66:137-147.
42. Roush W. New knockout mice point to molecular basis of memory. Science 1997, 275:32-33.
43. Bliss T.V.P. Young receptors make smart mice. Nature 1999, 401:25-27.
44. Lee Y.S., Silva A.J. The molecular and cellular biology of enhanced cognition. Nat Rev Neurosci 2009, 10:126-137.
45. Kaur B., Singh N., Jaggi A.S. Exploring mechanism of pioglitazone-induced memory restorative effect in experimental dementia. Fundam Clin Pharmacol 2009, 23:557-566.
46. Susswein A.J., Katzoff A., Miller N., Hurwitz I. Nitric oxide and memory. Neuroscientist 2004, 10:153-162.
47. Tan S.E. Roles of hippocampal nitric oxide and calcium/calmodulindependent protein kinase II in inhibitory avoidance learning in rats. Behav Pharmacol 2007, 18:29-38.
48. Staay F.J., Rutten K., Erb C., Blokland A. Effects of the cognition impairer MK-801 on learning and memory in mice and rats. Behav Brain Res 2011, 220:215-229.
49. Ellison G. The N-methyl-d-aspartate antagonists phencylidine, ketamine and dizolcipine as both behavioral and anatomical models of dementia. Brain Res Rev 1995, 20:140-267.
50. Hlinak Z., Krejci I. Concurrent administration of subeffective doses of scopolamine and MK-801 produces a short-term amnesia for the elevated plus-maze in mice. Behav Brain Res 1998, 91:83-89.
51. Coyle J.T., Price D.L., DeLong M.R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983, 219:1184-1190.
52. Davies P., Maloney A.J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976, 25:1403.
53. Reisine T.D., Yamamura H.I., Bird E.D., Spokes E., Enna S.J. Pre- and postsynaptic neurochemical alterations in Alzheimer's disease. Brain Res 1978, 159:477-481.
54. Blokland A. Acetylcholine: a neurotransmitter for learning and memory?. Brain. Res Rev 1996, 21:285-300.
55. Kopelman M.D., Corn T.H. Cholinergic 'blockade' as a model for cholinergic depletion. A comparison of the memory deficits with those of Alzheimer-type dementia and the alcoholic Korsakoff syndrome. Brain 1988, 111:1079-1110.
56. Kim M.J., Choi S.J., Lim S.T., Kim H.K., Kim Y.J., Yoon H.G., et al. Zeatin supplement improves scopolamine-induced memory impairment in mice. Biosci Biotechnol Biochem 2008, 72:577-581.
57. Pathan A.R., Viswanad B., Sonkusare S.K., Ramarao P. Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced memory impairment in rats. Life Sci 2006, 79:2209-2216.
58. Allahtavakoli M., Shabanzadeh A., Roohbakhsh A., Pourshanazari A. Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats. Basic Clin Pharmacol Toxicol 2007, 101:309-314.
59. Aoun P., Simpkins J.W., Agarwal N. Role of PPAR-ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells. Invest Ophthalmol Vis Sci 2003, 44:2999-3004.